Helix BioMedix, Inc. announced that it has entered into a manufacturing and supply agreement with Peptisyntha, Inc. Helix BioMedix, Inc. is a developer of bioactive peptides, while Peptisyntha, Inc. is an affiliate of Solvay S.A. Pursuant, and will manufacture and supply to Helix BioMedix its conditions for specific peptides at agreed upon prices for an initial term of two years.
“This agreement is significant for Helix BioMedix as it addresses several critical components that are important to the company both now and in the future,” stated R. Stephen Beatty, President and CEO of Helix BioMedix, Inc. “First, our relationship with Peptisyntha is a major step towards ensuring that we can supply commercial quantities of peptides once products are developed through our pharmaceutical program. Second, this agreement will immediately provide peptide supplies to our marketing partners for our rapidly growing consumer product segment. Current indications lead us to believe that our consumer product revenue could exceed $1 million in 2008 and could be in excess of $5 million in 2009. As a result of this agreement, our partners will have a readily available peptide supply for the significantly higher order volume that we are now beginning to experience.”
Helix BioMedix, Inc. is a development stage company that engages in the development and commercialization of consumer and pharmaceutical products containing peptides and peptide fragments. They primarily offer small proteins known as bioactive peptides. The peptide’s are use for anti-aging skin care, acne treatment, wound healing, and treatment for athlete’s foot as well as other fungal infections to the skin and hair. The company is also active in developing peptides for a variety of therapeutic and industrial product categories, including oral care, biocides, and animal health. The company’s headquarters are located in Bothell, Washington and was founded in 1988.
Let us hear your thoughts below: